Fintel reports that on October 20, 2025, JP Morgan upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Underweight to Neutral. Analyst Price Forecast Suggests 18.55% Downside As of ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $10.84 / share. This is an increase of 48.75% from the prior estimate of $7.29 dated September 27, 2025. The ...

Replimune (REPL) stock underwent a major rally on Monday after the biotechnology company announced results from its resubmission of a Biologics License Application (BLA) for “RP1 in combination with ...

Replimune received FDA acceptance for its RP1 BLA resubmission in advanced melanoma, with a PDUFA date set for April 2026. REPL stock surged nearly 100% on the news, but FDA acceptance only restarts ...

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...

Replimune Group (REPL) has drawn attention after presenting updated clinical data from its IGNYTE phase 2 trial at the ESMO Congress 2025. The study combined RP1 with nivolumab in patients with acral ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in UnitedHealth Group Inc (Symbol: UNH), where a total volume of 92,988 contracts has ...

Replimune Group announced that the U.S. Food and Drug Administration has accepted the resubmission of its Biologics License Application for RP1 in combination with nivolumab, targeting advanced ...

I am selling my remaining shares in TARS for 90% gain. I am adding to my position in DERM on the dip back to $7. I am initiating a new position in REPL with 5% portfolio weighting. REPL- FDA's ...